FULLER H B CO
No enriched coverage for $FUL in the last 7 days.
No SEC Form 4 filings for $FUL in the last 30 days.
See all $FUL insider activity →H.B. Fuller (FUL) rejected Ancora Holdings' $1.1B-$1.2B offer for its BAS unit, citing undervaluation and operational concerns. BAS reported 6% organic growth in Q2, and FUL's board argues a sale would create dis-synergies. Ancora may continue its campaign, pressuring FUL to prove BAS's value.
H.B. Fuller (FUL) director Teresa J. Rasmussen Trangsrud received 1,171.25 stock units valued at $56.35 each, convertible to common stock 1-for-1 upon certain events. She now holds 26,122.92 stock units and 3,391.433 common shares. The award is part of the company's deferred compensation plan.
H.B. Fuller (FUL) reported that director Daniel L. Florness received a grant of 390.420 stock units on August 28, 2026, at $56.35 per unit. These units convert into common stock on a 1-for-1 basis. After the grant, Florness holds 33,616.060 stock units and 1,351 shares of common stock directly.
Recent FUL coverage spans mergers & acquisitions, financial news and insider activity.
Rejection may keep the stock stable or cause short‑term volatility as activist pressure continues.
Small insider award with modest dollar value; unlikely to move the stock materially.
The grant represents a modest dilution and a small increase in insider ownership; unlikely to move the stock.
The grant represents a modest $27k value and adds to existing holdings, causing negligible dilution and limited price impact.
Rejection likely supports current share price and may deter future low‑ball offers.
AlphAI scores every news story that mentions FUL with an AI model for sentiment and relevance, and aggregates insider trades from FULLER H B CO's SEC EDGAR Form 4 filings. Figures refresh continuously.
H.B. Fuller (FUL) rejected Ancora Holdings' $1.1B-$1.2B offer for its BAS unit, citing undervaluation and operational concerns. BAS reported 6% organic growth in Q2, and FUL's board argues a sale would create dis-synergies. Ancora may continue its campaign, pressuring FUL to prove BAS's value.
3 min readH.B. Fuller (FUL) director Teresa J. Rasmussen Trangsrud received 1,171.25 stock units valued at $56.35 each, convertible to common stock 1-for-1 upon certain events. She now holds 26,122.92 stock units and 3,391.433 common shares. The award is part of the company's deferred compensation plan.
1 min readH.B. Fuller (FUL) reported that director Daniel L. Florness received a grant of 390.420 stock units on August 28, 2026, at $56.35 per unit. These units convert into common stock on a 1-for-1 basis. After the grant, Florness holds 33,616.060 stock units and 1,351 shares of common stock directly.
1 min readH.B. Fuller (FUL) director Michael J. Happe received 488 stock units worth $56.35 each on August 28, 2026, under a directors' compensation plan. These units convert to common stock 1:1 upon certain events. Happe now holds 18,329 stock units and 1,343 shares directly.
1 min readH.B. Fuller's board rejected an unsolicited bid for its BAS segment, citing a valuation below market precedent and lack of financing details. The board highlighted BAS's 6% organic growth and 10% EBITDA improvement, noting its importance for future earnings. The board also cited operational integration challenges and reaffirmed its strategic priorities, including the Advanced Medical Solutions acquisition and Project Quantum Leap.
1 min readH.B. Fuller Co. (NYSE:FUL) shares were unchanged in premarket trading after its board rejected Ancora Holdings Group's $1.2 billion bid for its building adhesives unit, citing undervaluation and lack of growth potential consideration. Ancora criticized the rejection as irrational and emphasized its ability to finance a higher offer. The bid aimed to help H.B. Fuller reduce debt and focus on integrating Advanced Medical Solutions Group Plc.
1 min readH.B. Fuller (NYSE:FUL) said Advanced Medical Solutions Group plc (LSE:AMS) shareholders approved the proposed cash acquisition of AMS. The approval is a milestone toward closing, which H.B. Fuller expects by year end, subject to remaining conditions and regulatory approvals. H.B. Fuller reported 2025 revenue of $3.5B.
2 min readWeaver Nathan D. (Exec VP, Business Transform.) sold 9,561 shares of FULLER H B CO (FUL) at $62.06 ($0.59M total) on 2026-08-11.
2 min readH.B. Fuller shares fell about 1.3% after activist Ancora Holdings disclosed a formal cash offer to buy the company’s Building Adhesive Solutions segment for $1.1 billion to $1.2 billion, escalating a dispute over strategy. Separately, AMS shareholders approved H.B. Fuller’s recommended cash acquisition of Advanced Medical Solutions Group with 84.23% voting in favor. Macro CPI was in line.
4 min readAncora Holdings Group proposed, via a letter to H.B. Fuller’s board, to buy H.B. Fuller’s Building Adhesive Solutions unit for $1.1 billion to $1.2 billion in cash, per Bloomberg. Ancora said the sale could reduce H.B. Fuller’s debt and help it focus on integrating Advanced Medical Solutions Group Plc. The deal is subject to approvals and due diligence.
4 min read
